| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05148195 Details | 2024-03-13 Interventional | 2 | 86 | Calcium Docetaxel Irinotecan Leucovorin Levoleucovorin Neoplasms Advanced Solid … | The study was terminated due to the sponsor's research and development strategy adjustment. - | |||
| NCT04761601 Details | 2024-03-13 Interventional | 1 | 32 | Gemcitabine Paclitaxel Neoplasms Advanced Solid … | Stopped for strategic business reasons. The decision to stop the study was not connected to any
safety concerns, or new risk associated with the study product, intervention, or procedures. - | |||
| NCT04612725 2020-000169-17 Details | 2024-03-13 Interventional | 2 | 159 | Benralizumab Chronic Urticar… Urticaria Chronic Spontan… | Study did not meet primary endpoint The study was terminated early by the sponsor as the primary analysis results did not support the continued development of benralizumab for the indication of CSU. | |||
| NCT04529954 Details | 2024-03-13 Interventional | 1/2 | 20 | Valproic Acid Epilepsies, Par… Epilepsy Focal Epilepsy | Company Decision - | |||
| NCT04197986 2019-003248-63 Details | 2024-03-13 Interventional | 3 | 39 | Infigratinib Carcinoma Carcinoma, Tran… Urinary Bladder… Upper Tract Uro… Urothelial Blad… | The sponsor has decided to close the study due to the discontinuation of infigratinib
development. The discontinuation of the study was not due to safety reasons. - | |||
| NCT04172597 Details | 2024-03-13 Interventional | 2 | 1 | Antidiarrheals Loperamide Breast Neoplasm… Breast Cancer Colorectal Canc… Glioblastome Mu… Solid Tumor | Strategic business decision (unrelated to safety) - | |||
| NCT04060849 Details | 2024-03-13 Interventional | 1 | - | Ethanol Pharmaceutical … Neoplasms Hematopoietic a… Malignant Solid… Solid Neoplasm | Enrollment temporarily on hold, pending protocol and study document updates - | |||
| NCT03533946 Details | 2024-03-13 Interventional | 2 | 7 | Rucaparib Prostatic Neopl… Prostate Cancer | New standard of care for study participant population - | |||
| NCT02923739 Details | 2024-03-13 Interventional | 2 | 9 | Albumin-Bound P… Antibodies Antibodies, Mon… Antineoplastic … Bevacizumab Endothelial Gro… Immunoglobulin … Immunoglobulins Paclitaxel Adenocarcinoma Adenocarcinoma,… Adenocarcinoma,… Brenner Tumor Carcinoma Carcinoma, Endo… Carcinoma, Tran… Cystadenocarcin… Cystadenocarcin… Recurrence Fallopian Tube … Fallopian Tube … Fallopian Tube … Fallopian Tube … Fallopian Tube … Fallopian Tube … Fallopian Tube … Malignant Ovari… Ovarian Adenoca… Ovarian Clear C… Ovarian Endomet… Ovarian Mucinou… Ovarian Seromuc… Ovarian Serous … Ovarian Transit… Ovarian Undiffe… Primary Periton… Recurrent Fallo… Recurrent Ovari… Recurrent Prima… | The study was terminated early by the Sponsor - | |||
| NCT02574910 Details | 2024-03-13 Interventional | 1 | - | Abiraterone Ace… Adrenal Hyperpl… Adrenocortical … Adrenogenital S… Hyperplasia Congenital Adre… | Need to update IND - | |||
| NCT02451111 2015-001487-19 Details | 2024-03-13 Interventional | 2 | 190 | Ibrutinib Rituximab Lymphoma Lymphoma, Folli… Follicular Lymp… | The premature termination is based on the decision by the SAKK board on November 14, 2020 due
to the lack of further financial support for the follow up period. - | |||
| NCT02230930 Details | 2024-03-13 Interventional | 2 | 13 | Apomorphine Hydrocortisone Hydrocortisone … Hydrocortisone … Hydrocortisone … Parkinson Disea… Apomorphine-ind… Parkinson's Dis… | Delayed inclusion - stopped when 10 patients completed the study - | |||
| NCT06036511 Details | 2024-03-12 Interventional | 1/2 | 0 | Ketamine Stress Disorder… PTSD | Per PI, this trial will not be started at UNM due to change in institutional responsibilities
of the PI - | |||
| NCT05979415 Details | 2024-03-12 Interventional | 2 | 8 | Apomorphine Parkinson Disea… | Administrative decision - | |||
| NCT05085002 Details | 2024-03-12 Interventional | 2 | 100 | Fulvestrant Letrozole Breast Neoplasm… Advanced Breast… | The study is being closed based on corporate changes at EQRx and is not related to any efficacy
or safety issues with lerociclib. - | |||
| NCT04933227 Details | 2024-03-12 Interventional | 2 | 29 | Atezolizumab Capecitabine Oxaliplatin Adenocarcinoma Stomach Neoplas… Gastric Cancer Gastroesophagea… | Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2. - | |||
| NCT04137978 Details | 2024-03-12 Interventional | 2/3 | 0 | Potassium Citra… Cystinuria | Unspecified business decision/strategic reason - | |||
| NCT04102436 Details | 2024-03-12 Interventional | 2 | 0 | Aldesleukin Cyclophosphamid… Fludarabine Urogenital Neop… Breast Cancer Endocrine/Neuro… Gastrointestina… Non-Small Cell … Ovarian Cancer | Difficulty with availability of GLP-grade reagents for manufacturing. - | |||
| NCT04014361 Details | 2024-03-12 Interventional | 1 | 36 | Itraconazole Healthy | HUAA study is terminated early due to a business decision. A strategic business decision was made to terminate the study prior to initiation of the multiple-ascending dose study (Part C). The secondary objectives pertaining to Part D were not evaluated as the study was terminated before the commencement of Part D. | |||
| NCT03982992 2017-002314-31 Details | 2024-03-12 Interventional | 2 | 0 | Blinatumomab Leukemia Leukemia, Lymph… Neoplasm, Resid… Precursor Cell … Acute Lymphobla… Acute Lymphobla… Acute Lymphobla… B Cell Precurso… B-Cell Acute Ly… | Lack of potential study subjects due to a change of standard of care treatment outside of
clinical trials. - |